Welcome to tagrissoandme.co.uk*
This website is intended only for UK patients who have been prescribed TAGRISSO® (osimertinib)
*This website has been produced and funded by AstraZeneca UK.
Unlike Chemotherapy, osimertinib is a personalised treatment option which is a type of targeted cancer therapy specifically for patients with Epidermal Growth Factor Receptor (EGFR) mutations. Osimertinib is an EGFR-targeted medicine known as a protein kinase inhibitor (PKI), also known as EGFR PKI. Osimertinib is not chemotherapy.1,2
Osimertinib is not chemotherapy or immunotherapy.1,2
Osimertinib is used in adult patients to treat:1,2
- After complete removal of your cancer as a post-surgical (adjuvant) treatment.1,2
- As the first medicine you receive for your cancer which has spread to other parts of the body.1,2
- If your cancer has progressed while you were being treated with other protein kinase inhibitor medicines, it means that your cancer contains a gene defect called ‘T790M’. Because of this defect, other protein kinase medicines may no longer work.1,2
What are targeted therapies?
Targeted therapies are treatments designed for specific types of cancer. Targeted therapies work on certain types of cancer to block the growth and spread of cancer cells. Targeted therapies are not chemotherapy or immunotherapy.5-8
How does osimertinib work?
Osimertinib works by blocking EGFR and may help to slow or stop your lung cancer from growing. It may also help to reduce the size of the tumour and prevent the tumour from coming back after removal by surgery.1,2
Osimertinib is a once-daily pill1
Osimertinib may fit conveniently into your daily routine, and you may be able to take it at home. You can take your pill with or without food, so there’s no need to plan your meals around your treatment.1
References:
- Tagrisso 40 mg and 80 mg film coated tablets. Summary of product characteristics.
- Tagrisso 40 mg and 80 mg film coated tablets. Patient Information Leaflet.
- Cancer Research UK (CRUK). Stages and grades of lung cancer. Last reviewed: 28 Jan 2020. Available at: https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/stages-grades Accessed December 2023.
- ESMO Patient Guide Series based on the ESMO Clinical Practice Guidelines. What is Non-Small-Cell Lung Cancer? Available at: https://www.esmo.org/content/download/7252/143219/1/EN-Non-Small-Cell-Lung-Cancer-Guide-for-Patients.pdf Accessed December 2023.
- NIH. Targeted Therapy to Treat Cancer. Available at: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#what-is-targeted-therapy Accessed December 2023
- NIH NCI Dictionary. Targeted therapy. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/targeted-therapy Accessed December 2023
- NIH NCI Dictionary. Immunotherapy. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunotherapy Accessed December 2023
- NIH NCI Dictionary. Chemotherapy. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chemotherapy Accessed December 2023.
GB-73011 I DOP: January 2026
Reporting side effects
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of medicines.
Side effects can also be reported to AstraZeneca in the following ways:
No imagery of real patients has been used on this site.
© AstraZeneca 2026. All rights reserved
GB-76796| DOP: October 2026
